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We have studied how spontaneous or carcinogen-induced intestinal tumorigenesis was affected by genetic or diet-induced obesity
in C57BL/6J-𝐴𝑝𝑐𝑀𝑖𝑛/+ X C57BL/6J-𝐿𝑒𝑝𝑜𝑏/+ mice. Obesity was induced by the obese (ob) mutation in the lep gene coding for the
hormone leptin, or by a 45% fat diet. The effects of obesity were examined on spontaneous intestinal tumors caused by themultiple
intestinal neoplasia (Min) mutation in the adenomatous polyposis coli (Apc) gene and on tumors induced by the dietary carcinogen
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). F1 ob/ob (homozygous mutated) mice had increased body weight (bw)
and number of spontaneous and PhIP-induced small intestinal tumors (in 𝐴𝑝𝑐𝑀𝑖𝑛/+ mice), versus ob/wt (heterozygous mutated)
and wt/wt mice (homozygous wild-type). A 45% fat diet exacerbated bw and spontaneous tumor numbers versus 10% fat, but not
PhIP-induced tumors. Except for bw, ob/wt and wt/wt were not significantly different. The obesity caused hyperglucosemia and
insulinemia in ob/ob mice. A 45% fat diet further increased glucose, but not insulin. Inflammation was seen as increased TNF𝛼
levels in ob/ob mice. Thus the results implicate disturbed glucose regulation and inflammation as mechanisms involved in the
association between obesity and intestinal tumorigenesis. Ob/ob mice had shorter lifespan than ob/wt and wt/wt mice.
1. Introduction
Obesity is defined as an excess accumulation of adipose
tissue. The rate of obesity has more than doubled over the
past 20 years in most OECD countries [1]. More than half of
the adult population are overweight (with body mass index
(BMI) 25–29.9 kg/m2) or obese (with BMI ≥ 30 kg/m2), and
about 18% of both genders are obese. Rates of overweight and
obesity among children are also increasing; average reported
overweight rates (including obesity) increased from 13% in
2001-2002 to 15% in 2009-2010 for 15-year-olds (based on age-
and gender-specific cut-off points for BMI) [1].
A parallel increase in overweight/obesity andmany forms
of cancer has been observed in most countries around the
world in the past two to three decades. Cancer is now
the second leading cause of mortality in the OECD countries
[1]. In Norway, colon cancer is the second most prevalent
cancer for women, after breast cancer, and the third most
prevalent cancer for men, after prostate and lung cancer
[2]. In the experiment described in this paper, we have
examined how obesity may affect intestinal tumorigen-e-
sis.
Obesity alters the physiology of the whole organism, and
therefore animal models are required to study the effects
of increased adiposity. In addition, models that integrate
lifestyle and genetic factors in a singlemodel systemprovide a
physiologically intact system valuable for studies of complex
relationships. In the present work, we have studied the
relationship between obesity and intestinal tumorigenesis in
the double-mutant F1 offspring obtained by crossing a mouse
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model for intestinal tumorigenesis and a mouse model for
obesity.
The well-established model for intestinal tumorigene-
sis, the C57BL/6J-ApcMin/+ mouse, is heterozygous for the
germline nonsense mutation multiple intestinal neoplasia
(Min) in the tumor suppressor gene adenomatous polyposis
coli (Apc) leading to a truncated nonfunctional APC protein,
and therefore develops numerous spontaneous intestinal
tumors [3, 4]. Apc is a key component in the Wingless-
related integration site (Wnt) signaling pathway [5, 6]. The
Minmouse is a model for the inherited disorder familial ade-
nomatous polyposis (FAP), as well as for sporadic colorectal
cancer in humans [7, 8], and develops multiple adenomas
in the small intestine and to a much lesser degree in the
colon.
The Min mouse was crossed with the C57BL/6J-Lepob/+
mouse, heterozygous for the obese (ob) mutation in the leptin
(lep) gene, which becomes obese when having a homozy-
gous mutation (ob/ob) and therefore lacks functional leptin
hormone [9–11]. In addition to being obese, the ob/ob mice
are reported to exhibit hyperphagia, a transient diabetes-like
syndrome of hyperglycemia, glucose intolerance, elevated
plasma insulin, subfertility, impaired wound healing, and
increased hormone production from pituitary and adrenal
glands, and apparently they are hypometabolic and hypother-
mic [12]. Leptin regulates food intake and energy expenditure
and has effects on immune functions, including inflamma-
tion, and reproduction [11, 13].
Obesity is caused by an imbalance between caloric intake
and energy expenditure, which is influenced by both genetic
and environmental factors. In this work, we have used two
models for obesity. By studying obesity induced genetically
in the ob mouse, we could examine the effect of obesity
on intestinal tumorigenesis independent of diet. In addition,
we studied environmentally-induced obesity, that is, diet-
induced obesity (DIO), by giving the F1 mice either a 45%
fat diet or a control 10% fat diet as adults (from weaning to
termination).
In addition to the effects on spontaneous intestinal
tumors caused by the inherited mutated Apc gene in the
Min/+ mice, the effect of obesity was also examined on
tumors induced by the environmental (dietary) factor formed
during cooking of meat and fish, the mutagenic, genotoxic
and carcinogenic heterocyclic amine 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) [14]. Previously, we
have reported that PhIP increased intestinal tumorigenesis
in adult C57BL/6J-Min/+ mice [15] and that theMin/+ mice
were much more susceptible to PhIP if exposed neonatally
[16, 17] than as young adults [15, 17].
In this work, we have studied obesity as an end point in
itself, and as a factor impacting on intestinal tumorigenesis.
The obesity was either caused genetically by the inherited ob
mutation or environmentally by a 45% fat diet. We exam-
ined whether genetically-or diet-induced obesity increased
spontaneous or carcinogen-induced intestinal tumorigen-
esis in the Min X ob mice. Furthermore, we examined
two hypotheses for the relationship between obesity and
intestinal tumorigenesis: disturbed blood glucose regulation
and increased inflammation. In addition, we have examined
the impact of heterozygous or homozygous ob mutation on
long-term survival ofmice with or withoutmutatedApc gene.
2. Materials and Methods
2.1. Mice. The Min (multiple intestinal neoplasia) pedigree
was bred at The Norwegian Institute of Public Health, Oslo,
Norway, bymating C57BL/6J-Apc+/+ (B6J, wild-type) females
with C57BL/6J-ApcMin/+/J (stock 002020) males purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). To
minimize the genetic drift away from the colony at the Jack-
son Laboratory, both females andmales in the breeding stock
at our institute were replaced regularly. Mice with the obese
(ob) mutation in the leptin (lep) gene, B6.V-Lepob/+/J (stock
000632), were also purchased fromThe Jackson Laboratory.
2.2. Experimental Groups. In total, 48 experimental groups
were included in this experiment: 6 genotypes (Apc+/+ X
𝐿𝑒𝑝
𝑤𝑡/𝑤𝑡, Apc+/+ X 𝐿𝑒𝑝𝑜𝑏/𝑤𝑡, Apc+/+ X Lepob/ob, ApcMin/+ X
𝐿𝑒𝑝
𝑤𝑡/𝑤𝑡, ApcMin/+ X 𝐿𝑒𝑝𝑜𝑏/𝑤𝑡, or ApcMin/+ X Lepob/ob) × 2
genders (females or males) × 2 treatments (0.9% NaCl or
PhIP) × 2 diets (a 10% fat or a 45% fat diet). Homozygous
mutant ApcMin/Min mice die during the embryo stages [18],
whereas homozygous Lepob/ob (ob−/−) mice are viable [9, 11].
The Min mutation was propagated through males to avoid
that the resulting intestinal adenomas and anemia might
interfere with pregnancy in females [3]. Mice with leptin-
deficiency (genetically induced obesity), that is, the Lepob/ob
mice, were used to study the effects of obesity separated
from the influence of diet. Six genotype combinations were
obtainable from crosses between Min mice and ob mice, via
two generations. First, Apc+/+ X ob+/− females and ApcMin/+ X
ob+/+ males were crossed.Then themice that were included in
the experimental groups were produced by crossing ofApc+/+
X ob+/− females and ApcMin/+ X ob+/− males. To separate
the wild-type (normal, nonmutated) allele of the ob gene
from the wild-type allele of the Apc gene, throughout this
paper the wild-type allele of the ob gene is designated “wt”,
whereas the wild-type allele of Apc is designated “+.” The
three ob genotypes obtained were wt/wt (homozygous wild-
type), ob/wt (heterozygousmutated) andob/ob (homozygous
mutated), and the two Apc genotypes obtained were +/+
(homozygous wild-type) andMin/+ (heterozygousmutated).
Breeding of the experimental mice continued until
approximately 11 mice per experimental group were obtained
(number based on power analysis and experience with this
model); however, to achieve this some groups ended up with
higher numbers.The number ofmice (𝑛) per treatment group
is given in the text and in figure legends and tables, for each
end point.
2.3. Genotyping, Housing and Termination of the Mice. All
Min X ob F1 offspring were genotyped for both Min and
ob status by allele-specific polymerase chain reaction (PCR)
analysis. DNA was extracted from ∼2mm2 samples obtained
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by ear puncture for identification of individual mice at wean-
ing and kept on ice. The samples were suspended in 60 𝜇L
TE-buffer with sodium dodecyl sulfate (SDS) (10mM Tris
pH 7.4, 0.1mM EDTA pH 8.0, 0.05% SDS) and incubated at
95∘C for 10min.Then aliquots of 6𝜇L of 10mg/mLProteinase
K (Sigma-Aldrich Corp., St. Louis, MO, USA) were added
and the samples incubated at 56∘C overnight. Finally, the
samples were incubated at 95∘C for 10min to inactivate the
enzyme and stored at −20∘C until PCR amplification. The
PCR reactions for genotyping ofApc statuswere carried out as
described previously [19]. For ob genotyping, the PCR reac-
tionswere carried out on an EppendorfMastercycler gradient
(Eppendorf AG, Hamburg, Germany) as follows. Genomic
DNA (5 𝜇L of 1 : 100 dilution of isolated DNA) was amplified
in a 10 𝜇L reaction volume per sample, which contained final
primer concentrations of 0.9 𝜇M of each of the following
primers: oIMR1151 (5󸀠-TGTCCAAGATGGACCAGACTC-
3󸀠) and oIMR1152 (5󸀠-ACTGGTCTGAGGCAGGGAGCA-
3󸀠), purchased from Eurogentec s.a. (Seraing, Belgium),
0.2 𝜇M of dCTP, dGTP, dTTP, and dATP (Promega Corp.,
Madison, WI, USA), 1x DyNazyme II Hot Start Reaction
buffer (15mM Tris-HCl (pH 8.2), 30mMKCl, 2.5mMMg2+,
5mM (NH
4
)SO
4
and 0.02% bovine serum albumin (BSA)),
and 0.008U/𝜇L DyNazyme II Hot Start DNA polymerase
(both from Thermo Fischer Scientific Inc., Waltham, MA,
USA). The amplification conditions were 10min at 94∘C
before 35 cycles at 94∘C for 15 sec, 64∘C for 30 sec and 72∘C
for 23 sec, followed by a final extension at 72∘C for 5min.
After the PCR amplification, 10𝜇L PCR products and 5 𝜇L
restriction enzyme mix, which in the final concentration
of 15𝜇L volume contained 0.56x buffer D, 0.06mg/mL
BSA and 0.23U Dde I enzyme (Promega Corp.), were
incubated for 12 h. The PCR products were visualized by
electrophoresis through a 2.2% agarose gel (Lonza FlashGel
system, Lonza, Basel, Switzerland). The wild-type (wt/wt)
mice were identified as having a 155 bp PCR product, the
heterozygous mutated (ob/wt) mice with the 155 bp, a 100 bp
and a 55 bp PCR product, and the homozygous mutated
(ob/ob) mice as having a 100 bp and a 55 bp PCR product.
The reagents were purchased from Sigma-Aldrich Corp. (St.
Louis, MO, USA), Fluka (Buchs SG, Switzerland) and Pro-
mega Corp. (Madison, WI, USA), if not stated otherwise.
The littermates of the same gender were housed up to
5 mice per cage in 100% PET plastic disposable cages on
Nestpak Aspen 4HK bedding (Datesand Ltd., Manchester,
UK) in air flow IVC racks (Innovive Inc., San Diego, CA,
USA). The room had 12-h light/dark cycle and controlled
humidity (55 ± 5%) and temperature (20–24∘C). Water and
feed were given ad libitum to all mice.
The mice in the experimental groups were terminated at
11 weeks of age, before onset of noticeable anemia caused by
their tumors. Blood was sampled by cardiac puncture under
anesthesia with ZRF cocktail (containing 3.3mg zolazepam,
3.3mg tiletamine, 0.5mg xylazine and 2.6 𝜇g fentanyl per
mL 0.9% NaCl) into Microvette Lithium Heparin tubes for
plasma from Sarstedt AS (Ski, Norway) for cytokine and
hormone analyses. Thereafter, the mice were sacrificed by
cervical dislocation.
2.4. Ethics Statement. The study was performed in strict
accordance with the laws and regulations for animal exper-
iments in Norway. The protocols were approved by the
Norwegian Animal Research Authority (NARA) (permit
numbers 1357 and 4856). Cardiac puncture and cervical
dislocation were performed under ZRF cocktail anesthesia,
before dissection of organs after death. Every effort was made
to minimize suffering.
2.5. Dietary Carcinogen. 2-Amino-1-methyl-6-phenylimid-
azo[4,5b]pyridine hydrochloride (PhIP-HCl) (CAS no.
105650-23-5), Cat. no. 163-15951, of >99% purity was pur-
chased from Wako Chemicals GmbH (Neuss, Germany).
PhIP-HCl was dissolved in distilled water, and the pH was
adjusted to approximately 4.0.
2.6. Breeding and Experimental Diets. The breeding pairs, as
well as their offspring until weaning at three weeks of age,
were fed a breeding diet, 2018 Teklad Global 18% Protein
Rodent Diet from Harlan Industries Inc. (Indianapolis, IN,
USA). The mice bred for obtaining breeding pairs, not
included in the experimental groups, were given a standard
maintenance diet, SDS RM1 (E) from SDS Special Diets
Services (Essex, UK), after weaning.
In addition to genetically-induced obesity caused by the
ob mutation, we also studied the effects of diet-induced
obesity (DIO), more relevant to the obese condition in most
humans. Approximately every other litter of mice included
in the experimental groups was given either a 45% fat diet
or a 10% fat diet from weaning and until termination at 11
weeks. In order to make sure the effects observed were due
to higher fat at the expense of carbohydrate only, and not
decreases in proteins, vitamins orminerals, diets were chosen
that added fat as % Atwater fuel energy (AFE) with isocaloric
exchange with carbohydrate. The high fat diet used was
45% AFE fat diet, code 824053 (45% kcal from fat, 20% kcal
from proteins, 35% from carbohydrate, 4.54 kcal AFE/g), for
comparison with the normal fat diet 10% AFE fat diet, code
824050 (10% kcal from fat, 20% kcal from proteins, 70% from
carbohydrate, 3.68 kcal AFE/g), both from SDS Special Diets
Services.
2.7. Feed and Water Intake. Since the 45% fat diet crumbled
easily it was not possible to determine the feed intake in a
reliable way by weighing the feed in and out of the cages.
Instead, feed and water intake were recorded in a selection of
mice from each treatment group kept in metabolic cages for
24 h at age 9–11 weeks, after getting accustomed to the cages
the day before. Urine volume was measured and urine and
feces were collected for later use not reported in this paper.
2.8. Obesity Determined as Area under the Curve (AUC),
Terminal Body Weight and Body Mass Index (BMI). Body
weight was recorded weekly from weaning at 3 weeks of
age to termination at 11 weeks of age for all ApcMin/+ and
Apc+/+ mice. At termination, nasoanal lengths were recorded
for calculation of body mass index (BMI), defined as body
weight divided by the nasoanal length squared (in g/cm2).
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Since different indicators of obesity might be more or less
suited for evaluation of its relationship with end points such
as intestinal tumorigenesis, we evaluated the body weight
data in three different ways. The body weight data were
analysed as area under the curve (AUC) for body weight
recorded from 3 to 11 weeks of age, calculated using the
macro in SigmaPlot 12.3 (Systat Software Inc., San Jose, CA,
USA), which integrates the area under the curve using the
trapezoidal rule. In addition, the body weight data were
evaluated as terminal body weight and terminal BMI at 11
weeks (data not shown).
2.9. Induction and Scoring of Intestinal Tumors. F1 pups
from Min X ob crosses were given a single subcutaneous
(s.c.) injection of 25mg/kg bw PhIP on day 3–6 after birth,
for evaluation of effects of obesity on carcinogen-induced
tumors. Separate litters were given a s.c. injection of 0.9%
NaCl as vehicle controls for scoring of spontaneous tumors
only.
The colon and small intestine were removed separately,
rinsed in ice-cold phosphate-buffered saline (PBS) and slit
open along the longitudinal axis. Intestinal tissues were then
spread flat between sheets of filter paper and fixed for at least
48 h in 10% neutral buffered formalin prior to staining with
0.2% methylene blue (Sigma-Aldrich Norway AS). Number,
diameter, and localization of tumors in small intestine and
colon were scored by transillumination in an inverse light
microscope at a magnification of ×20. The scoring was done
in order of consecutive mouse numbers unaware of their
treatment. Diameters of tumors were scored with an eyepiece
graticule. Tumor position along the intestines was registered
in cm from the stomach. For each experimental group,
incidence of tumors (number of mice with tumors/number
of mice in the group), tumor number (mean number of
tumors/mouse ± SD) and tumor diameter in mm (mean of
all tumors in all mice in the group ± SD) were calculated,
for small intestine and colon separately. In addition, size of
the tumors was illustrated by curves of distributions of tumor
size classes (of 0.25mm tumor diameter intervals) calculated
as mean number of tumors in each tumor size class for each
treatment group. In the C57BL/6J strain, the small intestine
is the main target organ for tumorigenesis caused by theMin
mutation as well as by PhIP, and very few tumors were found
in the colon.Therefore, the colonic tumor data are not shown.
2.10. Glucose Tolerance Test (GTT) and Nonfasted Blood
Glucose Measurements. A glucose tolerance test (GTT) was
performed on a selection of mice from all treatment groups
at age 6 weeks. These mice were fasted for 6 h (8-9 a.m. to 2-
3 p.m.) and were given an intraperitoneal (i.p.) injection of
2 g/kg bw D-(+)-glucose (Sigma-Aldrich Norway AS, Oslo,
Norway). Glucose in blood obtained by puncture of the
saphenous vein was measured with a glucometer (FreeStyle
Freedom Lite (Abbott Diabetes Care Inc., Alameda, CA,
USA) 5min before and 15, 30, 60 and 120min after the
glucose injection. The area under the glucose tolerance
curve (AUC) was calculated from −5 to 120min, using the
macro in SigmaPlot 12.3. When readings were >27.8mmol/L,
displayingHIGH in the glucometer, this valuewas used in the
data analysis. This was found for 5, 2 and 48% of the samples
in one or several time points in wt/wt, ob/wt and ob/ob
mice, respectively. No samples had glucose readings below
1.1mmol/L and showing LOW in the glucometer. Nonfasted
blood glucose levels were also measured in all mice at both
age 6 and 11 weeks.
2.11. Urine Glucose Measurements. In cases with raised blood
glucose concentrations, for instance, in diabetes, glucose may
be found in the urine when its concentration in plasma
exceeds the renal threshold. In some mice showing high
values of blood glucose, urine glucose was also measured by
urinalysis dipsticks Siemens Multistix 8 SG purchased from
Siemens Healthcare Diagnostics Inc. (Tarrytown, NY, USA).
2.12. Insulin and Insulin-Like Growth Factor (IGF-1) Anal-
yses. Insulin and insulin-like growth factor 1 (IGF-1) were
measured in plasma obtained from the mice at sacrifice.
ELISA kits from MyBioSource Inc. (San Diego, CA, USA)
were used according to the manufacturer’s instructions.
Optical density (OD) was measured at 450 nm on a BioTek
microplate reader (BioTek Instruments Inc., Winooski, VT,
USA). Concentrations were calculated from standard curves
on each plate. All samples were diluted 1 : 5 in PBS, pH 7.1.The
limit of detection was 0.1 ng/mL for both insulin and IGF-1.
2.13. Cytokine Analyses. The proinflammatory cytokines
interleukin-1𝛽 (IL-1𝛽), interleukin-6 (IL-6) and tumor necro-
sis factor 𝛼 (TNF𝛼) were measured in plasma obtained
from the mice at sacrifice. Bead-based immunoassays BD
Cytometric Bead Array (CBA), from BD Biosciences, San
Jose, CA, USA, were used according to the manufacturer’s
instructions. Data were collected on a BD LSRII flow cytome-
ter (BD Biosciences) and analysed by use of FCAP Array
software 3.0 (BD Biosciences). All samples were diluted 1 : 2
in Assay Diluent included in the CBA kit. The limits of
detection were 1.9, 1.4 and 2.8 pg/mL, for IL-1𝛽, IL-6 and
TNF𝛼, respectively.
2.14. Long-Term Survival of Untreated ob Mice. The impact
of the ob genotype on life-span was examined in groups of
untreatedApcMin/+ andApc+/+ mice, of all three ob subgroups,
ob/ob, ob/wt and wt/wt, and both genders. The mice were
kept under regular observation and euthanized by cervical
dislocation when deterioration in general health or quality
of life were reached, as judged by clinical observations, body
condition and symptoms such as weight loss, dehydration
or hunched posture. Survival of each genotype of mice
(in days) was depicted as decreasing % of surviving mice
compared with the number of mice present at the start of the
experiment.
2.15. Statistical Analyses. Thedata for each end point (such as
body weight, blood glucose levels and tumor numbers) was
evaluated on several levels; first on all mice and then further
on several strata; age, Apc genotype, 0.9% NaCl or PhIP
treatment, gender, ob genotype and % fat diet. The results
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Table 1: Feed and water intake in mice kept in metabolic cages for 24 h.
ob genotype % fat diet Gender 𝑛 Feed intake(g feed/g bw/day)
Feed intake
(kcal AFE/g bw/day) n
Water intake
(mL/g bw/day)
wt/wt 10 F 10 0.25 ± 0.04 0.90 ± 0.13 10 0.25 ± 0.05
M 11 0.18 ± 0.05 0.65 ± 0.19 11 0.20 ± 0.04
ob/wt 10 F 10 0.22 ± 0.03 0.82 ± 0.12 11 0.27 ± 0.06
M 14 0.20 ± 0.05 0.72 ± 0.18 15 0.22 ± 0.06
ob/ob 10 F 11 0.17 ± 0.04 0.62 ± 0.14 11 0.31 ± 0.16
M 8 0.16 ± 0.02 0.59 ± 0.06 9 0.23 ± 0.10
wt/wt 45 F 12 0.10 ± 0.02 0.44 ± 0.11 12 0.18 ± 0.04
M 13 0.07 ± 0.03 0.30 ± 0.14 8 0.13 ± 0.04
ob/wt 45 F 12 0.09 ± 0.03 0.41 ± 0.14 11 0.15 ± 0.05
M 14 0.07 ± 0.03 0.30 ± 0.13 10 0.12 ± 0.02
ob/ob 45 F 11 0.05 ± 0.02 0.25 ± 0.07 2 0.24 ± 0.08
M 8 0.07 ± 0.02 0.31 ± 0.08 4 0.12 ± 0.01
Feed and water intake (mean ± SD) were recorded in some of the mice from each treatment group kept in metabolic cages for 24 h at age 9–11 weeks, after they
were getting accustomed to the cages the day before. There were no consistent significant differences in feed and water intake between 𝐴𝑝𝑐𝑀𝑖𝑛/+ and 𝐴𝑝𝑐+/+
mice, or between 0.9% NaCl- or PhIP-treated mice, and therefore these data were pooled. F = females, M = males, and 𝑛 = number of mice.
are reported down to the most specific combination of these
parameters for which statistically significant differences were
found. Because of this complexity, statistical comparisons
cannot be shown in a meaningful way on the figures or
in Table 1, which give the numerical data. However, the 𝑃
values of all comparisons are given in the text. All data
were presented as mean ± SD, except for the cytokine and
insulin data wheremedian and single values were shown, and
were analysed using SigmaPlot 12.3. Student’s 𝑡-test orMann-
Whitney Rank sum test for nonparametric data was used for
testing of the survival data. The incidence of colonic tumors
was analysed by Fischer exact test (two-tailed probability).
Simple and multiple linear regression were used to examine
the associations between body weight, glucose, insulin and
cytokine levels and number or diameter of small intestinal
tumors. For all other data, analysis of variance (ANOVA) was
used with an appropriate multiple comparison procedure.
When testing the influence of a single factor, one-way
ANOVA with the Holm-Sidak test for multiple comparisons
was used for parametric data or the Kruskal-Wallis ANOVA
on ranks with Dunn’s test for multiple comparisons was used
for nonparametric data. When testing the influences of two
or three factors together the data were analysed by two- or
three-wayANOVA, respectively, with theHolm-Sidak test for
multiple comparisons. A 𝑃 value of < 0.05 was considered
statistically significant.
3. Results
3.1. Feed and Water Intake. The feed and water intake were
recorded in mice kept in metabolic cages for 24 h. When the
feed and water intake data were evaluated as g feed or mL
water/g bw/day, there were no significant differences in feed
orwater intake betweenApcMin/+ andApc+/+mice, or between
0.9% NaCl- or PhIP-treated mice. Therefore, the data were
pooled for Apc genotype and 0.9% NaCl or PhIP treatment,
and stratified only for gender, ob genotype and % fat diet
(Table 1).
The feed intake per g bw was higher in females than in
males, based on all mice (𝑃 < 0.001), and in the subgroups
ob/wt (𝑃 = 0.009) and wt/wt (𝑃 < 0.001) mice, but not in
ob/ob mice. A higher feed intake per g bw in females than in
males was also found in a previous experiment [19].
Mice fed a 10% fat diet had significantly higher feed intake
than mice fed a 45% fat diet (𝑃 < 0.001). This was also seen
in the subgroups ob/ob, ob/wt and wt/wt mice, exposed to
either 0.9% NaCl or PhIP (𝑃 < 0.001, for all comparisons).
The ob/ob mice had significantly lower feed intake per
g bw compared with ob/wt and wt/wt mice (𝑃 < 0.001,
for both comparisons), whereas ob/wt and wt/wt mice were
not significantly different. In females separately, the results
were the same as for all mice, whereas in males separately,
the differences between the three ob genotypes did not reach
significance. The feed intake per mouse was significantly
higher in ob/ob mice than in ob/wt and wt/wt mice, but
because of the extreme body weight of the ob/ob mice, the
intake was lower on a body weight basis.
When the feed intake was compared as intake of kcal/g
bw during 24 h, the results were essentially the same as for g
feed/g bw (Table 1).
The water intake per g bw was higher in females than in
males, based on all mice (𝑃 < 0.001), and in the subgroups
of mice on a 10% fat diet and on a 45% fat diet (𝑃 < 0.001
and 𝑃 = 0.012, resp.), and in the subgroup of ob/ob mice
(𝑃 = 0.003) (Table 1).
Mice fed a 10% fat diet had significantly higher water
intake per g bw than mice fed a 45% fat diet (𝑃 < 0.001).
The ob/ob mice had significantly higher water intake per
g bw compared with ob/wt and wt/wt mice (𝑃 = 0.010 and
𝑃 = 0.009, resp.), whereas ob/wt and wt/wt mice were not
significantly different. On the individual level, we observed
that many, but not all, of the ob/ob mice had a much higher
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Figure 1: Body weight as area under the curve (AUC). Body weight was recorded weekly from weaning at week 3 until termination at week
11 and is presented for ApcMin/+ (a) females and (b) males, and Apc+/+ (c) females and (d) males (mean ± SD). The mice were exposed to 0.9%
NaCl and given a 10% fat diet (white columns) or 0.9% NaCl and a 45% fat diet (light grey columns), or they were exposed to PhIP and given
a 10% fat diet (dark grey columns) or PhIP and a 45% fat diet (black columns). 𝑛 = 10–18 mice. a.u. = arbitrary units.
water intake as well as higher urine output than ob/wt and
wt/wt mice, especially mice with blood glucose above normal
levels. This condition appeared to be transient.
3.2. Obesity Determined as Area under the Curve (AUC),
Terminal Body Weight and Body Mass Index (BMI). Body
weight was compared between the treatment groups (𝑛 =
10–18) by calculating the area under the curve (AUC) for
the body weight development from weaning at week 3 to
termination at week 11 (Figure 1). For this end point, data
from both ApcMin/+ and Apc+/+ were evaluated. The ApcMin/+
mice were lighter than the Apc+/+ mice (𝑃 < 0.001). There
were no differences between mice treated with 0.9% NaCl or
PhIP, based on all mice and in the subgroups ob/ob, ob/wt,
and wt/wt mice. AUC was higher for males than females
based on all mice (𝑃 < 0.001), in the subgroups ob/ob, ob/wt,
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Figure 2: Number of small intestinal tumors. The number of small intestinal tumors (mean ± SD) is shown for (a) female and (b) male
ApcMin/+ mice with the three ob genotypes, terminated at 11 weeks of age.Themice were exposed to 0.9% NaCl and given a 10% fat diet (white
columns) or 0.9% NaCl and a 45% fat diet (light grey columns), or they were exposed to PhIP and given a 10% fat diet (dark grey columns)
or PhIP and a 45% fat diet (black columns). 𝑛 = 10–17 mice.
and wt/wt mice (𝑃 < 0.001, for all three comparisons), and
in all three ob genotypes on a 45% fat diet and for ob/wt and
wt/wt on a 10% fat diet (𝑃 < 0.001, for all comparisons), but
not for ob/ob mice on a 10% fat diet.
AUC was significantly higher in ob/ob mice compared
with ob/wt and wt/wt mice based on all mice (𝑃 < 0.001)
(Figure 1), in female mice (𝑃 < 0.001) and in male mice
(𝑃 < 0.001) separately (𝑃 values similar for both genotype
comparisons). The ob/wt mice had higher AUC than the
wt/wt mice based on all mice (𝑃 = 0.003), in females (𝑃 =
0.050), but not in males, separately, in mice on a 10% fat diet
(𝑃 = 0.040), but not inmice on a 45% fat diet, and not inmice
treated with either 0.9% NaCl or PhIP, separately.
Mice fed a 45% fat diet were heavier than mice fed a
10% fat diet based on all mice (𝑃 < 0.001) (Figure 1), in
both female and male ob/ob mice (𝑃 < 0.001, for both
comparisons), and in male wt/wt mice (𝑃 = 0.005).
There were significant interactions between ob genotype
and gender (𝑃 = 0.011), ob genotype and % fat diet (𝑃 ≤
0.001) and ob genotype and treatment with 0.9% NaCl or
PhIP (𝑃 = 0.027).There was a significant interaction between
gender, % fat diet and ob genotype (𝑃 = 0.019), where the
gender X % fat diet interaction depended on the ob genotype
(𝑃 ≤ 0.001, for all three ob genotypes).
In addition to evaluating body weight as AUC, the
terminal body weight and terminal BMI (data not shown)
were also calculated for comparison.The body weight results
were very much the same whether the data were evaluated as
AUC from week 3 to 11 (Figure 1), terminal bw or terminal
BMI at 11 weeks (data not shown), except that there was no
difference in BMI between ob/wt andwt/wtmice. In addition,
BMI was higher in ob/ob females than in males, whereas
ob/obmales were larger than females for body weight as AUC
and terminal body weight.
3.3. Small Intestinal Tumors in ApcMin/+ Mice. All ApcMin/+
mice (𝑛 = 10–17 in each experimental group), regardless
of ob genotype, % fat diet, or 0.9% NaCl or PhIP treatment,
had small intestinal tumors (adenomas), confirming 100%
incidence of small intestinal tumors as is usually found in
the ApcMin/+ mice [15, 16, 19]. No tumors were found in
the Apc+/+ mice. The number of small intestinal tumors was
not significantly different between female and male ApcMin/+
mice (Figures 2(a) versus 2(b)). There were no significant
interactions between gender and PhIP treatment, % fat diet
or ob genotype for this end point.
The number of small intestinal tumors was significantly
higher in ob/ob mice compared with ob/wt mice, based on
all mice (𝑃 < 0.001), in PhIP-treated mice (𝑃 < 0.001) and in
0.9%NaCl-treated mice (𝑃 = 0.002), separately, and in ob/ob
mice compared with wt/wt mice, for all mice (𝑃 < 0.001),
in PhIP-treated mice (𝑃 < 0.001) and in 0.9% NaCl-treated
mice (𝑃 < 0.001), separately (Figure 2). The number of small
intestinal tumors was not significantly different in ob/wtmice
compared with in wt/wt mice, based on all mice or in PhIP-
treated or 0.9% NaCl-treated mice separately. There was a
borderline significant interaction between ob genotype and
PhIP treatment (𝑃 = 0.049).
The 45% fat diet increased the number of small intestinal
tumors compared with the 10% fat diet, in all mice (𝑃 <
0.001), in vehicle-treated mice (𝑃 < 0.001), but not in PhIP-
treated mice. There was a significant interaction between %
fat diet and PhIP treatment (𝑃 = 0.007).
PhIP increased the number of small intestinal tumors
comparedwith the vehicle 0.9%NaCl, in allmice (𝑃 < 0.001),
inmice given a 10% fat diet (𝑃 < 0.001) and a 45% fat diet (𝑃 <
0.001). PhIP increased the number of small intestinal tumors
in ob/ob mice (𝑃 < 0.001), in ob/wt mice (𝑃 < 0.001) and
in wt/wt mice (𝑃 < 0.001), and in both females (𝑃 < 0.001,
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for all three comparisons) and males (𝑃 < 0.001, for all three
comparisons) of each ob genotype (Figure 2).
The small intestinal tumors had diameters of 0.15–
4.30mm. The statistical evaluation of differences in small
intestinal tumor size between the experimental groups is
described in the following (data not shown). In addition, this
is illustratedwith size distribution curves (Figure 3). Based on
all mice, the small intestinal tumors were significantly larger
inmale mice compared with in female mice (𝑃 < 0.001).This
was observed within all the PhIP-exposed mice (𝑃 < 0.001),
also among the subgroups of PhIP-treated ob/ob mice (𝑃 <
0.001), ob/wt mice (𝑃 = 0.006) and wt/wt mice (𝑃 < 0.001),
but not in 0.9% NaCl-treated mice. The males had larger
tumors than the females also in the subgroup of ob/ob mice
on a 10% fat diet (𝑃 < 0.001) andon a 45% fat diet (𝑃 < 0.001),
in ob/wtmice on a 45% fat diet (𝑃 < 0.001), and inwt/wtmice
on a 10% fat diet (𝑃 < 0.001).
The diameter of the small intestinal tumors was signif-
icantly higher in all ob/ob mice compared with ob/wt and
wt/wt mice (𝑃 < 0.001, for both comparisons), but not in
ob/wt compared with wt/wt mice (Figure 3, data not shown).
The effect of diet on the size of the small intestinal
tumors was evaluated for both genders and is illustrated
with size distribution curves for the females in Figures 3(a)
and 3(b). The diameter of the small intestinal tumors was
not significantly different between mice on a 10% fat diet
versus on a 45% fat diet, based on all mice. Some statistically
significant differences were observed in various subgroups,
but these differences were not consistent in direction with
regard to % fat diet and may therefore be due to chance. The
tumors were not significantly larger after a 45% fat diet in
the 0.9% NaCl-exposed or in the PhIP-exposed subgroups of
mice. But this was the case in PhIP-exposed ob/wt and wt/wt
mice (𝑃 < 0.001, for both comparisons), but not for the PhIP-
exposed ob/ob mice. Both female and male ob/ob mice had
significantly smaller tumors after a 45% fat diet compared
with a 10% fat diet (𝑃 < 0.001, for both comparisons),
possibly indicating formation of new tumors.
The effect of PhIP exposure on the size of the small intesti-
nal tumors was evaluated for both genders and is illustrated
with size distribution curves for the males in Figures 3(c)
and 3(d). Based on all mice, the small intestinal tumors were
significantly larger after PhIP exposure compared with 0.9%
NaCl exposure (𝑃 < 0.001).This was also observed in females
and males separately, and in mice on a 10% fat diet and a 45%
fat diet separately (𝑃 < 0.001, for all comparisons).The small
intestinal tumorswere significantly larger after PhIP exposure
compared with 0.9% NaCl exposure in all ob/ob mice (𝑃 <
0.001), in ob/wt mice on a 10% fat diet (𝑃 < 0.001) and a
45% fat diet (𝑃 < 0.001), and in wt/wt mice on 45% fat diet
(𝑃 < 0.001). Within each gender separately, this was also the
case for the subgroups of all three ob genotypes (𝑃 < 0.001,
for all comparisons).
There were significant statistical interactions between %
fat diet, gender and ob genotype (𝑃 ≤ 0.001), PhIP treatment,
gender and ob genotype (𝑃 = 0.008), PhIP treatment, % fat
diet and ob genotype (𝑃 ≤ 0.001), between PhIP treatment
and gender (𝑃 = 0.009), and between PhIP treatment and %
fat diet (𝑃 = 0.036), for this end point.
3.4. Colonic Tumors in ApcMin/+ Mice. In the C57BL/6J strain,
the small intestine is the main target organ for tumorigenesis
caused by the Min mutation as well as by PhIP. Very few
tumors were found in the colon in this experiment (Figure 4),
adding no additional insight. Therefore, the data for inci-
dence, number and size of the colonic tumors are not shown.
3.5. Localization of Tumors in the Small Intestine and Colon.
In mice given the 10% fat diet, the majority of small intestinal
tumors were localized in the distal two-thirds, that is, in
middle and distal parts, of the small intestine (Figure 4), as
is usually observed in the ApcMin/+ mouse [15, 16, 19]. In
the ob/ob mice, there were unusually high numbers of small
intestinal tumors also in the proximal part, whereas in ob/wt
and wt/wt mice there were much fewer tumors in this area.
This distribution of tumors was observed both in 0.9% NaCl-
treated (Figure 4(a)) and PhIP-treated (Figure 4(b)) mice,
and after both treatments the tumor numbers were higher in
this area with a 45% fat diet compared with a 10% fat diet.
The few colonic tumors present were localized mainly in the
middle to distal part of the colon.
3.6. Glucose Tolerance Test (GTT) and Nonfasted Blood Glu-
cose. Based on the AUC values from the GTT test performed
at 6 weeks of age, AUC in ApcMin/+ mice were higher than
in Apc+/+ mice, and AUC in PhIP-treated mice was higher
than in 0.9% NaCl-treated mice; however, these comparisons
did not reach statistical significance. The data for ApcMin/+
and Apc+/+ mice were therefore pooled in the curves of blood
glucose levels after challenge (Figure 5).There were 5–9 mice
in each experimental group, except 4 in one group; female
wt/wt mice exposed to PhIP and a 45% fat diet. In GTT, there
was no significant difference (n.s.) between the genders, but
the general tendency based on all mice was higher levels in
males than in females, differing between the subgroups with
females higher than males in ob/ob mice (n.s.), and males
higher than females in ob/wt (𝑃 = 0.002) and wt/wt mice
(n.s.).
The ob/ob mice showed a much slower decrease in blood
glucose than both the ob/wt and wt/wt mice (𝑃 < 0.001,
for both comparisons) (Figure 5). This was also observed in
females and males separately, and in mice on 45% fat diet
(𝑃 < 0.001, for all comparisons). The ob/wt and wt/wt mice
were not significantly different. In mice on a 10% fat diet,
only the difference between ob/ob and wt/wt mice reached
significance (𝑃 < 0.001). The male ob/wt mice had actually
higher AUC than ob/ob mice both after treatment with 0.9%
NaCl and PhIP on the 10% fat diet (Figures 5(b) and 5(d)).
Mice on a 45% fat diet had a slower blood glucose
decrease after challenge than mice on a 10% fat diet (𝑃 <
0.001) (Figure 5). This was also observed in the subgroups
ob/ob mice, ob/wt mice and wt/wt mice (𝑃 < 0.001, for
all comparisons). Strikingly, the ob/ob mice on a 45% fat
diet in particular had much higher and prolonged blood
glucose levels after challenge, indicating severe blood glucose
dysregulation in both genders (Figure 5).
Therewas a significant interaction between gender and ob
genotype (𝑃 = 0.002) and between% fat diet and ob genotype
(𝑃 < 0.001) in the GTT data.
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Figure 3:The size of the small intestinal tumors.This is illustrated by curves of distributions of tumors size classes (of 0.25mm tumor diameter
intervals) calculated as mean number of tumors in each tumor size class for each treatment group.The effect of a 45% fat diet compared with
a 10% fat diet is shown for female ApcMin/+ X Lepob/ob mice (I), ApcMin/+ X Lepob/wt (󳵻) and ApcMin/+ X Lepwt/wt mice (◻) on a 10% fat diet, and
the same genotypes on a 45% fat diet (filled symbols) exposed to (a) 0.9% NaCl, or (b) PhIP. The effect of exposure to PhIP compared with
0.9% NaCl is shown for male ApcMin/+ X Lepob/ob mice (I), ApcMin/+ X Lepob/wt (󳵻) and ApcMin/+ X Lepwt/wt mice (◻) exposed to 0.9% NaCl, or
the same genotypes exposed to PhIP (filled symbols) on (c) a 10% fat diet, or (d) a 45% fat diet. 𝑛 = 10–17 mice.
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Figure 4: Localization of tumors along the small intestine and colon.This is shown for pooled female and male ApcMin/+ X Lepob/ob mice (I),
ApcMin/+ X Lepob/wt (󳵻) and ApcMin/+ X Lepwt/wt mice (◻) on a 10% fat diet (open symbols) or a 45% fat diet (filled symbols) treated with (a)
0.9% NaCl or (b) PhIP. The tumor position is given as distance from the stomach measured in cm. Mean number of tumors/cm intestine for
the mice in each experimental group was scored. 𝑛 = 10–17 mice.
According to WHO [20], diagnostic criteria for humans
with impaired glucose tolerance (IGT) are 7.8–11.1mmol/L 2 h
after an oralGTTof 75 g glucose, and levels above 11.1mmol/L
confirm diabetes. Regarding these levels also relevant for
mice, we found IGT at the 2 h time point in the GTT in 17%
and 40%, 50% and 80%, 60% and 58%, 56% and 83%, 93% and
92%, and 100% and 82%, of the female and male mice, in the
treatment groups wt/wt, ob/wt and ob/ob given a 10% fat diet,
and wt/wt, ob/wt and ob/ob given a 45% fat diet, respectively.
A diabetic level of glucose at the 2 h time point in the GTT
was found in 0% and 0%, 20% and 20%, 20% and 50%, 0% and
33%, 21% and 67%, and 100% and 82%, of the female andmale
mice in the same treatment groups as above, respectively.
Nonfasted blood glucose levels were also measured in all
mice at both age 6 (𝑛 = 10–18) and 11 (𝑛 = 9–17) weeks
(data not shown). Based on all mice, there were higher blood
glucose levels measured at week 6 compared with at week 11
(𝑃 < 0.001), but this difference varied between the subgroups.
The ApcMin/+ mice had significantly higher blood glucose
levels than Apc+/+ mice at 11 weeks (𝑃 < 0.001), but not at 6
weeks, confirming theGTT results. Based on all data, this was
most pronounced in PhIP-exposed mice (𝑃 < 0.001), and in
the ob/ob mice (𝑃 < 0.001). However, at 11 weeks separately,
this difference between Apc genotypes was also found in the
wt/wt mice (𝑃 = 0.038), but not in the ob/wt mice.
PhIP-treated mice had significantly higher blood glucose
levels than 0.9% NaCl-treated mice (𝑃 < 0.001) at week 11,
but not at week 6, confirming the GTT results. This was also
observed in the subgroup ApcMin/+ mice (𝑃 < 0.001), in mice
given a 10% fat diet (𝑃 < 0.001) and in the ob/ob mice (𝑃 <
0.001), but not in the subgroupApc+/+ mice, inmice on a 45%
fat diet or in ob/wt and wt/wt mice.
The nonfasted blood glucose data for comparisons
between genders, ob genotypes and diets both at 6 and 11
weeks (data not shown) were essentially similar to the data
from the GTT test.
3.7. Urine Glucose. In some mice showing high values of
blood glucose, urine glucose was also measured by urinalysis
dipsticks. These were mostly ob/ob mice, and 15 of the 23
(65%) ob/ob mice examined had glucose in their urine,
whereas 8 of 23 (35%) had not. Among the ob/ob mice with
glucose in the urine, all were females and mostly of ApcMin/+
genotype and on 45% fat diet and had received either 0.9%
NaCl or PhIP. However, also two examined female Apc+/+
mice with wt/wt ob genotype on 45% fat diet exposed to 0.9%
NaCl had glucose in their urine.
3.8. Insulin and IGF-1. Insulin and IGF-1 levels were mea-
sured in plasma obtained from the mice at termination. Six
samples were analyzed from each experimental group with
ANOVA, three from each gender. The levels of IGF-1 were
below the limit of detection, 0.1 ng/mL, whereas insulin was
detected in all samples (Figures 6(a) and 6(b)). The ob/ob
mice had significantly higher levels of insulin than mice with
ob/wt or wt/wt genotypes based on all mice (𝑃 < 0.001, for
both comparisons), and also in the subgroups of both Apc
genotypes, both genders, both diet groups and in 0.9% NaCl-
treated mice (𝑃 values were <0.001–0.036). The ob/wt and
wt/wt mice were not significantly different. In PhIP-treated
mice, only the comparison between ob/ob and wt/wt reached
significance (𝑃 = 0.012). The Apc+/+ mice had higher insulin
levels than ApcMin/+ mice based on all mice (𝑃 = 0.028) and
in the subgroup ofmales separately (𝑃 = 0.031). PhIP-treated
mice had higher insulin levels than 0.9% NaCl-treated mice
based on all mice (𝑃 = 0.026).Males (Figure 6(b)) had higher
insulin levels than females (Figure 6(a)) based on all mice
(𝑃 = 0.015), and in the subgroups of Apc+/+ mice (𝑃 = 0.026)
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Figure 5: Blood glucose levels as area under the curve (AUC) from a glucose tolerance test (GTT). The GTT was performed on mice fasted
for 6 h at 6 weeks of age. Blood glucose was measured 5min before and 15, 30, 60 and 120min after an i.p. injection of 2 g/kg bw glucose.
The data were pooled for ApcMin/+ and Apc+/+ mice. The mice were treated with either 0.9% NaCl, (a) females and (b) males, or with PhIP, (c)
females and (d) males. The mice had ob genotype ob/ob (I), ob/wt (󳵻) or wt/wt (◻) and were given a 10% fat diet (open symbols) or a 45%
fat diet (filled symbols). 𝑛 = 4–9 mice.
and ob wt/wt mice (𝑃 = 0.009). There were no significant
differences in insulin levels between mice on a 10% or a 45%
fat diet.
3.9. Cytokines. The proinflammatory cytokines IL-1𝛽, IL-
6 and TNF𝛼 were measured in plasma obtained from the
mice at termination. Six samples were analyzed from each
experimental group with ANOVA, three from each gender.
The levels of IL-1𝛽 were below the limit of detection,
1.9 pg/mL, in all samples, whereas 78% and 46% of the
samples had detectable levels of IL-6 and TNF𝛼, respectively.
No statistically significant differences were found in levels of
IL-6 between any treatment groups (Figure 6(c)). Regarding
TNF𝛼, the ob/ob mice had significantly higher levels than
mice with ob/wt or wt/wt genotypes based on all mice
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Figure 6: Levels of insulin and the proinflammatory cytokines IL-6 and TNF𝛼 in plasma. Insulin levels (ng/mL) were measured with ELISA
in plasma obtained from the mice at termination, for (a) females and (b) males (median and individual values are shown as columns and
dots, resp.). IL-6 (c) and TNF𝛼 (d) levels (both in pg/mL) were measured with bead-based immunoassays and analysed by flow cytometer
in plasma obtained from the mice at termination. The data shown are from females and males combined (median and individual values are
shown as columns and dots, resp.). 𝑛 = 6mice (3 of each gender).
(𝑃 < 0.001, both comparisons), whereas ob/wt and wt/wt
were not significantly different (Figure 6(d)). The significant
difference in TNF𝛼 levels between mice with ob/ob genotype
and ob/wt or wt/wt genotypes was seen in the mice given
a 45% fat diet (𝑃 = 0.002, both comparisons), but not in the
mice given a 10% fat diet. We found no significant differences
in TNF𝛼 levels between mice exposed to 0.9% NaCl or PhIP
(Figure 6(d)).
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3.10. Correlations between Body Weight and Glucose, Insulin
and Cytokine Levels. The strength of the association between
the three different end points used for body weight and the
other end points examined in this experiment was evalu-
ated by simple linear regression (Table 2). The coefficient
of determination (𝑅2) expresses the % of variation in the
dependent variable than can be explained by the independent
variables. The percentage of the variation in the nonfasted
blood glucose levels measured at 6 weeks that could be
explained by the body weight data was 46–57%, in the blood
glucose levels measured at 11 weeks it was 33–43%, and in the
insulin levels it was 32–48%, depending on which parameter
was used for body weight (𝑃 < 0.001, for all comparisons).
The percentage of the variation in the TNF𝛼 levels that could
be explained by AUC and terminal body weight was around
20% (𝑃 = 0.021 and 𝑃 = 0.013, resp.), whereas for BMI this
association was not statistically significant.
3.11. Correlations between Body Weight, Glucose, Insulin and
Cytokine Levels and Intestinal Tumorigenesis. The strength
of the association between the body weight and the other
end points examined in this experiment and number and
diameter of small intestinal tumors was evaluated by simple
linear regression (Table 3). Body weight evaluated as AUC
fromweek 3 to 11 and nonfasted blood glucose levels at week 6
and week 11 could explain 11%, 12%, and 18% of the variation
in the number of small intestinal tumors, respectively (𝑃 <
0.001, for all three variables). When evaluating number of
small intestinal tumors with all three body weight parameters
and blood glucose at both 6 and 11 weeks together with
multiple linear regression, the association was statistically
significant for body weight as AUC, terminal bw and blood
glucose at 11 weeks (𝑃 < 0.001, for all three variables),
explaining 31% of the variation in tumor number.
The association found by simple linear regression with
diameter of small intestinal tumors and TNF𝛼, body weight
evaluated as AUC from week 3 to 11 and nonfasted blood
glucose levels at week 6 and week 11, was 31%, 14%, 9%
and 8%, respectively (𝑃 < 0.001, except for TNF𝛼 with
𝑃 = 0.003) (Table 3). When evaluating diameter of small
intestinal tumors with all three body weight parameters and
blood glucose at both 6 and 11 weeks together with multiple
linear regression, the association was statistically significant
for body weight as AUC and terminal bw (𝑃 < 0.001, for both
variables), explaining 21% of the variation in tumor diameter.
3.12. Long-Term Survival of Untreated ob Mice. For exami-
nation of impact of the ob genotype on life-span, groups of
untreated ApcMin/+ and Apc+/+ mice of all three ob genotypes
and both genders were kept under regular observation until
euthanized (𝑛 = 24–35 per experimental group). Survival
of each genotype of mice was depicted as decreasing % of
surviving mice compared with the number of mice present
at the start of the experiment (Figure 7). The life-span was
significantly shorter for all three ApcMin/+ X ob genotypes,
because of their intestinal tumors causing anemia and other
complications leading to early termination, compared with
the Apc+/+ X ob genotypes (𝑃 < 0.05, for all three
Table 2: Associations between various parameters for body weight
and glucose, insulin and cytokine levels.
AUC bw Terminal bw Terminal BMI
𝑅
2
𝑃 𝑅
2
𝑃 𝑅
2
𝑃
Terminal bw 0.91 <0.001
Terminal BMI 0.59 <0.001 0.62 <0.001
Glucose
6 weeks 0.46 <0.001 0.47 <0.001 0.57 <0.001
Glucose
11 weeks 0.33 <0.001 0.33 <0.001 0.43 <0.001
Insulin 0.34 <0.001 0.32 <0.001 0.48 <0.001
IL-1𝛽 0.00 n.s. 0.00 n.s. 0.01 n.s.
TNF𝛼 0.20 0.021 0.23 0.013 0.07 n.s.
Associations between various parameters for body weight (independent
variables) and glucose, insulin, and cytokine levels (dependent variables)
were examined with simple linear regression (SigmaPlot 12.3, Systat Software
Inc., San Jose, CA, USA). This was performed on pairs of end points from
all mice from all experimental groups from which individual data could be
paired. Body weight (bw) data were evaluated either as area under the curve
from week 3 to 11 (AUC bw), as terminal bw, or as terminal body mass index
(BMI) at 11 weeks of age. Nonfasted blood glucose was measured at 6 and 11
weeks of age. Insulin was measured with ELISA, and TNF𝛼 was measured
with flow cytometer, both in plasma obtained at termination at 11 weeks.
𝑅
2 = coefficient of determination, n.s. = not statistically significant.
comparisons). There were no significant differences between
the three ob genotypes either of ApcMin/+ or Apc+/+ genotype
when tested with one-way ANOVA. However, when tested
with Student’s 𝑡-test, or Mann-Whitney Rank sum test for
data that failed the normality test, the Apc+/+ ob/ob mice
had significantly shorter life-span than the Apc+/+ wt/wt and
ob/wt mice (𝑃 ≤ 0.001, for both comparisons), whereas
Apc+/+ ob/wt and wt/wt mice were not significantly different.
4. Discussion
In this experiment, we have studied obesity as an end point in
itself, and as a factor impacting on intestinal tumorigenesis.
The obesity was either caused genetically, that is, by the
inherited ob mutation in the lep gene, or caused by an
environmental factor, a 45% fat diet, given from weaning to
termination at 11 weeks of age.We have examined the effect of
the obesity on both spontaneous intestinal tumors caused by
the inherited Min mutation in the Apc gene, and on tumors
induced by themutagenic and carcinogen heterocyclic amine
PhIP found in cooked meat and fish.
4.1. Genetically-Induced Obesity. In this experiment, we have
evaluated obesity in three different ways: as body weight
development using AUC calculated from weaning at 3 weeks
to termination at 11 weeks of age, as terminal body weight
and terminal BMI. This was done because various indicators
of obesity, such as BMI, waist circumference and waist-to-
hip ratio, waist-height-ratio or percentage of body fat, have
been found to bemore or less strongly associated with human
study end points, and are therefore more or less suitable
as indicators of obesity. All the three studied body weight
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Table 3: Associations between body weight, glucose, insulin and cytokine levels and the number or diameter of small intestinal tumors.
Number of small intestinal tumors Diameter of small intestinal tumors
𝑅
2
𝑃 𝑅
2
𝑃
Diameter of tumors 0.51 <0.001 No. of tumors 0.51 <0.001
AUC bw 0.11 <0.001 AUC bw 0.14 <0.001
Terminal bw 0.05 <0.001 Terminal bw 0.07 <0.001
Terminal BMI 0.08 <0.001 Terminal BMI 0.10 <0.001
Glucose
6 weeks 0.12 <0.001
Glucose
6 weeks 0.09 <0.001
Glucose
11 weeks 0.18 <0.001
Glucose
11 weeks 0.08 <0.001
Insulin 0.03 n.s. Insulin 0.06 n.s.
IL-1𝛽 0.00 n.s. IL-1𝛽 0.01 n.s.
TNF𝛼 0.09 n.s. TNF𝛼 0.31 0.003
Associations between body weight parameters, glucose, insulin, and cytokine levels (independent variables) and the number or diameter of small intestinal
tumors (dependent variables) were examined with simple linear regression (SigmaPlot 12.3, Systat Software Inc., San Jose, CA, USA). This was performed on
pairs of end points from all mice from all experimental groups from which individual data could be paired. Number of small intestinal tumors is calculated as
number of tumors in each mouse, and tumor diameter is calculated as mean of all tumors in each mouse. Body weight (bw) data were evaluated either as area
under the curve from week 3 to 11 (AUC bw), as terminal bw, or as terminal body mass index (BMI) at 11 weeks of age. Nonfasted blood glucose was measured
at 6 and 11 weeks of age. Insulin was measured with ELISA, and TNF𝛼 was measured with flow cytometer, both in plasma obtained at termination at 11 weeks.
𝑅
2 = coefficient of determination, n.s. = not statistically significant.
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Figure 7: Survival of mice. Untreated pooled female and male ApcMin/+ and Apc+/+ mice of all three ob genotypes were kept under regular
observation until euthanized. Survival of each genotype of mice was depicted as decreasing % of surviving mice compared with the number
of mice present at the start of the experiment (𝑛 = 26, 30 and 31 for groups of ApcMin/+ X Lepob/ob (I), ApcMin/+ X Lepob/wt (󳵻) and ApcMin/+ X
Lepwt/wt (◻)mice, respectively, and 𝑛 = 35, 28 and 24 forApc+/+ X Lepob/ob (e),Apc+/+ X Lepob/wt (󳵳) andApc+/+ X Lepwt/wt (◼)mice, respectively.
parameters gave more or less the same differences between
the experimental groups (Figure 1, data not shown), except
that there was no difference in BMI between ob/wt and wt/wt
mice. In addition, BMI was higher in ob/ob females than in
males, whereas ob/obmales were larger than females for body
weight as AUC and terminal body weight.
The mice with a homozygous obmutation in the lep gene
have a deficiency in the hormone leptin. These ob/ob mice
were significantly heavier than the ob/wt and wt/wt, inde-
pendent of bodyweight parameter (Figure 1, data not shown),
reflecting the necessity of the leptin hormone formaintaining
normal body weight. However, when we measured the feed
intake for 24 h, the ob/obmice actually had significantly lower
intake of g feed or kcal/g bw than ob/wt and wt/wt mice
(𝑃 < 0.001, for both comparisons), whereas ob/wt and wt/wt
micewere not significantly different (Table 1).Theob/obmice
have been suggested to become obese because of hyperphagia
[12]; however, our data indicate that they become obese
despite of eating fewer grams of food and less calories per
g body weight. According to information from the breeder
[12], the ob/ob mice gain excess weight and deposit excess
fat even when restricted to a diet sufficient for normal
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weight maintenance in lean mice. However, lower level of
physical activity probably also contributes to the obesity in
the ob/obmice, since leptin is involved in regulation of energy
expenditure [11, 13], and we observed that the ob/ob mice
were much less physically active than the ob/wt and wt/wt
mice.
4.2. Diet-Induced Obesity (DIO). In addition to genetically-
induced obesity caused by the ob mutation, we also studied
the effects of diet-induced obesity (DIO), as an environ-
mental factor, more relevant to the obese condition in most
humans. The 45% fat diet significantly increased obesity,
evaluated by all three body weight parameters, compared
with the 10% fat control diet, based on all mice, in both
genders, and in most subgroups of mice, except that the AUC
for body weight was not significant in the subgroup of female
wt/wt mice and in the ob/wt mice of both genders (Figure 1,
data not shown).
DIO has been defined as a body weight of more than two
standard deviations above the average body weight of mice
fed a low-fat diet [21]. The ob/ob mice in all experimental
groups, except the female ApcMin/+ X ob/ob mice given 45%
fat diet and PhIP, fulfilled this strict definition, based on
terminal bw (data not shown). ForApcMin/+ X ob/wt or wt/wt,
of both genders, given 0.9% NaCl or PhIP, the mean in all
eight groupswas slightly below the bodyweight definingDIO,
whereas for the Apc+/+ X ob/wt or wt/wt, of both genders,
given 0.9% NaCl or PhIP, 5 of 8 experimental groups fulfilled
this definition. Except for the female andmaleApc+/+ Xob/wt
given 0.9% NaCl and 45% fat diet, and the male Apc+/+ X
wt/wt given PhIP and 45% fat diet, slightly lower body weight
can be explained by the fact that ApcMin/+ mice generally
have lower body weight than the Apc+/+ because of their
spontaneous intestinal tumors, affected even further with
PhIP [19].
Mice seem to eat a constant amount of calories.Therefore,
mice on a high fat diet would have a lower intake of food
measured as g feed compared with mice on a low-fat diet.
In this experiment, the mice fed a 45% fat diet had indeed
significantly lower intake of g feed than mice fed the control
10% fat diet on a body weight basis (Table 1). It would be
expected that the intake of the 45% fat diet was reduced until
the same intake of calories was reached as with the 10% fat
diet, but the intake of kcal/g bw/day was also significantly
lower in the mice given the 45% fat diet (Table 1). Therefore,
the observed difference in body weight between mice on a
10% fat and a 45% fat diet seems to be influenced also by
the type of diet (i.e., a higher content of fat at expense of
carbohydrates) and/or possibly reduced activity of the heavier
mice on the 45% fat diet. The body weight increase was
extreme in the ob/ob mice given the 45% fat diet, and their
level of physical activity was noticeably reduced.
The ob/ob mice on a 45% fat diet also showed transient
signs of diabetes, such as increased water intake and urine
output, and glucose in the urine, as also described by the
breeder [12]. However, there were no signs of the ob/ob mice
being more hypothermic than the ob/wt and wt/wt mice, as
described [12].They seemed to thrive on regular temperature
(20–24∘C).
A recent paper describing a meta-review of micro-array
data on high-fat DIO in C57BL/6J mice found that upregu-
lated genes were associated with fatty acid synthesis, inflam-
mation, signal transduction and transporters, and energy
homeostasis [22]. Down-regulated genes were associated
with sterol biosynthesis, insulin sensitivity and oxidative
stress. Peroxisome proliferator activated receptor (PPAR)𝛾
appeared to be a central obesity gene, interacting with lipid
metabolism and inflammation genes.
4.3. Intestinal Tumorigenesis. In the ApcMin/+ mice on the
C57BL/6J background, the small intestine, rather than the
colon, is the main target organ, and we therefore limit
our discussion to the small intestinal tumors. In our study,
homozygous mutation in the ob gene, causing deficiency in
the hormone leptin in the ob/ob mice, significantly increased
the number of spontaneous intestinal tumors and the number
of PhIP-induced tumors in ApcMin/+ mice compared with
the mice having normal (wt/wt) or lower (ob/wt) levels of
leptin (Figure 2). The tumor numbers were not significantly
different between the ob/wt and wt/wt mice.The 45% fat diet
further increased the number of small intestinal tumors based
on all mice, and in the 0.9% NaCl-treated mice, that is, the
spontaneous tumors. After PhIP exposure, the 45% fat diet
did not increase the tumor numbers further based on allmice,
and the response varied between the genotypes and genders
(Figure 2).
Females and males had the same number of small
intestinal tumors (Figure 2), but the tumorswere significantly
larger in males than in females, based on all mice (𝑃 < 0.001)
and in many of the subgroups (data not shown), indicating
a higher susceptibility in males to factors affecting tumor
growth. Epidemiological evidence indicates a higher risk in
men than in women for colorectal cancer [23, 24].
In the ob/ob mice, there were unusually high numbers
of small intestinal tumors proximally in the small intestine,
which were increased further with a 45% fat diet (Figure 4).
It could be speculated whether this is caused by the increased
secretion of bile acid into this small intestinal area caused by
the high fat diet, as has been suggested to cause intestinal
cancer [25].
The present data showed a consistent relationship
between obesity (Figure 1, data not shown) and number of
small intestinal tumors (Figure 2), both being increased in
the ob/ob mice compared with the ob/wt and wt/wt mice,
and the spontaneous tumors being further increased with the
45% fat diet.The same pattern was also observed in nonfasted
blood glucose levels (data not shown). Body weight evaluated
as AUC from week 3 to 11, and blood glucose levels at week
6 and week 11, showed the strongest association with number
of small intestinal tumors with 11%, 12% and 18%, respectively
(𝑃 < 0.001, all values) (Table 3).
In a previous study, similar results as in our study were
found by crossing a mouse with a different mutation in
the Apc gene (Apc1638N/+) with the C57BLKS-mLepdb/db mice,
carrying a mutation in the leptin receptor gene (Ob-Rb)
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causing both obesity and diabetes mellitus [26]. At 6 months
of age, these mice had increased numbers of tumors in their
small intestine, and also tumors in the stomach, cecum,
and colon, which were not seen in the Apc1638N/+ mouse.
In another study, the offspring from the crossing of the
same Min/+ mouse as we used (C57BL/6J-ApcMin/+) and
the C57BL/KsJ-db/db mouse, also having both obesity and
diabetes, had increased number of total and small intestinal
adenomas and increased incidence of colonic tumors at 15
months of age [27]. In these two studies, however, DIO was
not included.
In humans, overweight and/or obesity are associated with
increased risk, seen as increased incidence, mortality or poor
prognosis for many types of cancer, including colon cancer
[28–31]. Both body fatness and abdominal fatness have been
evaluated as convincing increasing risks of colorectal cancer
[32, 33].
4.4. Three Main Hypotheses for the Association between Obe-
sity and Intestinal Tumorigenesis. There seem to be numerous
signaling molecules and pathways through which obesity
may impact on cancer, and considerable cross-talk and con-
vergence between the pathways involved, ultimately ending
in increased cell proliferation, cell growth or angiogenesis, or
reduced apoptosis, and thus tumor promotion or progression.
At least three main hypotheses, mutually interconnected,
exist for the association between obesity and colorectal cancer
[28–31, 34]: (1) obesity has been suggested to be associated
with colon cancer via changes in adipokine levels released
from the adipose tissues locally or systemically, such as
increase in leptin and/or decrease in adiponectin, (2) that
disturbed blood glucose regulation observed as increased
serum levels of glucose, insulin and IGF-1 and insulin resis-
tance lead to increased proliferation and reduced apoptosis,
ultimately causing cancer, (3) or that obesity is a chronic
low-grade inflammatory state in the adipose tissues releasing
numerous proinflammatory cytokines, such as TNF𝛼, IL-6
and IL-1𝛽, affecting cancer. In addition, steroid hormones
such as estrogen and androgenmay be involved, but their role
in colon cancer is controversial.
Regarding the first hypothesis of changes in adipokine
levels as the link between obesity and colon cancer, we
investigated the influence of leptin by the use of leptin-
deficient mice. The diameter of the small intestinal tumors
was significantly higher in all ob/ob mice compared with
ob/wt and wt/wt mice (𝑃 < 0.001, for both comparisons)
(Figure 3, data not shown); thus, the obesity increased the
tumor size in spite of lack of growth-promoting leptin, in the
ob/obmice. As opposed to the ob/obmouse, commonobesity
in humans is characterized not by lack of leptin, but rather by
elevated levels of plasma leptin correlated with fat mass and
BMI, representing a form of leptin resistance [35, 36].
However, the causative role of increased leptin in colon
cancer is controversial and the data contradictory. Dysreg-
ulation of leptin or its receptors may contribute to colon
cancer via effects on growth and proliferation of cancer cells
via activation of signaling pathways, including JAK/STAT,
PI3-kinase/AKT, and/orMAPkinases [37]. Leptin stimulated
proliferation of human colon cancer cells in vitro and in
rat colon [38] and promoted motility and invasiveness of
human colon cancer cell lines [39], but had either potenti-
ating or inhibiting effect on growth of human cancer cells
from various other organs in vitro [40]. Leptin reduced
the development of aberrant crypt foci (ACF), precancerous
lesions in rat colon mucosa, induced by the carcinogen
azoxymethane (AOM) [41], and leptin was found not to be a
promotor in development of ACF in the colons of ob/ob and
db/db mice [42]. Others found that leptin acts as a growth
factor for colorectal tumors after initiationwithAOM inmice
[43].
In our experiment, the dietary fat is not affecting tumor
growth as such, since the diameter of the small intestinal
tumors was not significantly higher in mice on a 45% fat
diet compared with the 10% fat diet, based on all mice.
Some statistically significant differences were observed in the
various subgroups, but the differences were not consistent in
direction with regard to % fat diet. However, both female and
male ob/ob mice had significantly smaller tumors after a 45%
fat diet compared with a 10% fat diet (𝑃 < 0.001, for both
comparisons), possibly indicating formation of new tumors
(Figures 3(a) and 3(b), data not shown). It could be speculated
that lipotoxic free fatty acids from the 45% fat diet [28, 44, 45],
and/or the subsequent obesity [46], cause oxidative stress and
accumulation of reactive oxygen species (ROS), which may
lead to DNA damage and tumor initiation in the intestines.
Genes involved in lipid metabolism, phospholipase A2,
phospholipase C𝜀 and phospholipase D, have been shown to
modulate the intestinal tumor numbers by interacting with
the Wnt signaling pathway [47–49]. However, controversy
exists regarding the association between dietary animal fat
as such and human colon cancer [50]. It may be that other
factors than fat in the diet, such as heme iron in meat or
carcinogens produced by cooking ofmeat, or the total energy,
are also important for colon cancer.
The second hypothesis suggests that disturbed blood
glucose regulation may lead to increased proliferation and
reduced apoptosis, ultimately causing cancer. In our dynamic
assessment of glucose regulation using GTT, ob/ob mice
showed a much slower decrease in blood glucose than both
ob/wt and wt/wt mice (𝑃 < 0.001, for both comparisons)
(Figure 5). The nonfasted blood glucose levels were also
significantly higher in ob/obmice compared with both ob/wt
and wt/wt mice at both 6 and 11 weeks (𝑃 < 0.001 for
all comparisons) (data not shown), whereas there was no
difference between ob/wt and wt/wtmice, following the same
pattern as genetically induced-obesity.
Mice on a 45% fat diet had a slower blood glucose
decrease after challenge in GTT than mice on a 10% fat
diet (𝑃 < 0.001) (Figure 5). This was also observed in the
subgroups ob/ob mice, ob/wt mice and wt/wt mice (𝑃 <
0.001, for all comparisons).TheAUC inGTTwas remarkably
large in the ob/ob mice on a 45% fat diet (Figure 5), demon-
strating a markedly reduced ability to regulate blood glucose.
Nonfasted blood glucose levels were also significantly higher
in all mice on a 45% fat diet compared with a 10% fat diet at
both age 6 and 11 weeks (𝑃 < 0.001, for both comparisons)
(data not shown).
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The ob/ob mice had significantly higher levels of insulin
than mice with ob/wt or wt/wt genotypes, based on all mice
(𝑃 < 0.001, for both comparisons) (Figures 6(a) and 6(b)).
The ob/wt and wt/wt mice were not significantly different.
Therewere no significant differences in insulin levels between
mice on a 10% or a 45% fat diet. However, the effect of the
fat diets on insulin levels should be interpreted with caution
because of the low number of samples, especially from mice
on a 10% fat diet.
Overweight and obesity may cause secondary changes
such as hyperglycemia, hyperinsulinemia and insulin resis-
tance, and type 2 diabetes, whichmay lead to cancer develop-
ment [34, 51, 52].The hyperinsulinemiamay enhance synthe-
sis of insulin-like growth factor 1 (IGF-1) and its bioavailabil-
ity by decreasing the IGF binding proteins (IGFBP) [53, 54].
It is thought that macrophage-related inflammatory activities
in white adipose tissue (WAT) may contribute to obesity-
induced insulin resistance [55, 56]. Leptin can affect insulin
and glucose metabolism [57]. Studies have shown that both a
lack of leptin signals and adiposity as such may contribute to
insulin resistance and that decrease in central leptin signaling
can critically affect glucose metabolism in obese mice [58].
An overall increase in glucose by age 20 weeks versus 6
weeks reported in thewild-typeC57BL/6Jmouse [59]was not
clearly observed in our mice, since the glucose levels varied
with the genotypes; significantly higher at week 11 versus
week 6 in ob/wt mice (𝑃 = 0.017) or in the same direction
but nonsignificant in ApcMin/+ mice and wt/wt mice, whereas
higher levels were seen at week 6 compared with week 11 in
Apc+/+ mice (𝑃 < 0.001) and in the ob/ob mice (𝑃 < 0.001).
Hence, the genotypes, as well as the fat diets and/or the PhIP
treatment, affected these results.
We observed a higher level of nonfasted blood glucose in
male ob/wt and wt/wt mice compared with females both at
age 6 and 11 weeks (data not shown). The same tendency was
seen in the GTT.This gender difference is in accordance with
reference values of blood glucose in the wild-type C57BL/6J
mouse obtained both at 6 and 20 weeks of age [59]. However,
as opposed to the normal wild-type mice, the female ob/ob
mice had higher glucose levels than the males.
The ApcMin/+ mice had significantly higher nonfasted
blood glucose levels than Apc+/+ mice at 11 weeks (𝑃 < 0.001)
(data not shown). This was not caused by higher feed intake
since there were no significant differences in feed intake
between ApcMin/+ and Apc+/+ mice (Table 1), and the body
weight was lower in ApcMin/+ mice than Apc+/+ mice for
all three body weight scores (Figure 1, data not shown). A
possible explanation is that APC is involved in regulation of
epithelial glucose transport in the intestines, since ApcMin/+
mice had increased activity of the electrogenic glucose
carrier (SGLT1) compared with Apc+/+ mice [60]. Apc is a
component of the Wnt signaling pathway [5, 6]. Therefore,
other intriguing possibilities of a relationship between Apc
and blood glucose levels come from data showing that the
Wnt signaling pathway, which is as an important modulator
of adipocyte differentiation [61, 62], also influences endocrine
pancreas development and modulates mature 𝛽-cell func-
tions including insulin secretion, survival and proliferation,
and thereby may be involved in the pathogenesis of diabetes
[63]. Components of the Wnt signaling pathway may also be
involved in determining susceptibility to DIO [64].
The percentage of the variation in the blood glucose levels
at 6 weeks that could be explained by the body weight data
was 46–57%, and at 11 weeks it was 33–43%, depending on
which parameter was used for body weight (𝑃 < 0.001, for
all comparisons) (Table 2). The percentage of the variation in
the insulin levels that could be explained by the body weight
data was 32–48%, depending on which parameter was used
for body weight (𝑃 < 0.001, for all comparisons) (Table 2).
Body weight therefore seems to have a moderate effect on
blood glucose regulation.
Overall, the increase in body weight (Figure 1) and the
increased and prolonged blood glucose levels (Figure 5)
correlate well with the increased number of small intestinal
tumors (Figure 2).
In an epidemiological study, elevated insulin and glucose
were associated with increased risk of colorectal adenoma
and decreased apoptosis in normal rectal mucosa, indicat-
ing that insulin may act early in the adenoma-carcinoma
sequence to promote the development of colorectal adenoma
by decreasing apoptosis [65]. However, a diet high in foods
that increased postprandial insulin levels did not increase the
risk of colorectal cancer in a large prospective epidemiologi-
cal study [66].
In the third hypothesis, inflammation has been suggested
to be a causative link between obesity and colorectal cancer
[28–31, 34]. There are two types of evidence indicating
obesity as a chronic inflammatory illness: the release of
proinflammatory cytokines such as TNF𝛼, IL-6 and IL-1𝛽
from adipose tissues and infiltration of macrophages into the
WAT [67]. In our study, we found a significantly higher level
of TNF𝛼 in ob/obmice comparedwith ob/wt andwt/wtmice,
based on all mice, and in the subgroup of mice given a 45%
fat diet, but not in the mice given a 10% fat diet (Figure 6(d)).
The effect of the diets on TNF𝛼 should be interpreted with
caution because of the low number of samples from mice
on a 10% fat diet. The body weight data AUC and terminal
body weight could explain around 20% of the variation in
TNF𝛼 levels (𝑃 = 0.021 and 𝑃 = 0.013, resp.) (Table 2). The
variation in the number of small intestinal tumors could not
be explained by the TNF𝛼 levels, whereas 31% of the variation
in the diameter of small intestinal tumors could be explained
by the TNF𝛼 levels (𝑃 = 0.003) (Table 3). Thus, our data
support that inflammation is associated with obesity and the
size of small intestinal tumors.
After diet-induced obesity (60% fat diet) in C57BL/6
mice, increased expression in the colon of TNF𝛼 was found,
which instigated alterations in several components of the
Wnt signaling pathway leading to tumor transformation [68].
In a model with tumors induced by AOM and dextran
sulfate sodium (DSS) in lean (C57BL6/J) and ob/ob mice,
it was shown that when pathways involving TNF𝛼 were
inhibited, tumor numbers and proliferation and apoptosis
profiles were returned to levels observed in lean mice [69].
By looking at the temporal sequence of inflammation in
relation to tumorigenesis inMin/+mice, it was found that the
increased mRNA expression of the inflammatory cytokines
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TNF𝛼, IL-6, IL-1𝛽 and monocyte chemoattractant protein 1
(MCP-1) occurred at age 12 weeks in association with a rapid
increase in tumor number at the same time, and that, in
general, the overall tumor number and abundance of large
tumors were positively correlated with the inflammatory
cytokine responses [70]. Mice lacking TNF𝛼 because of a
targeted null mutation were protected from insulin resistance
caused by DIO or the ob/ob mutation [71]. However, a recent
review andmeta-analysis of epidemiological studies foundno
associations between colorectal cancer and TNF𝛼 and IL-6
[72].
We found no significant differences in TNF𝛼 levels
between mice exposed to 0.9% NaCl or PhIP (Figure 6(d)).
Also in rats, it was shown that inflammation did not precede
or accompany the induction of preneoplastic lesions in the
colon by PhIP [73].
4.5. Effects of Heterozygous ob Mutation. In our experiment,
the ob/wt mice were significantly heavier than wt/wt mice
when the body weight was evaluated as AUC (Figure 1) and
as terminal bw (data not shown), but not as terminal BMI
(data not shown). However, feed intake (Table 1), number
(Figure 2) and size (Figure 3, data not shown) of small
intestinal tumors, GTT results (Figure 5), nonfasted blood
glucose levels (data not shown), insulin (Figures 6(a) and
6(b)) and TNF𝛼 (Figure 6(d)) levels were not significantly
different between the ob/wt and wt/wt mice. Obviously, the
heterozygous state of the ob mutation in mice was able to
increase the body weight but was not severe enough to
negatively affect other end points, including intestinal cancer.
Others have also shown that the ob/wt mice partially
display the phenotype of the homozygous ob/ob mice, with
approximately 33% reduction in plasma leptin level when
adjusted for fat mass and 24% increase in percentage of body
fat adjusted for age and sex [74]. The homozygous condition
of ob/ob is found also in humans and is characterized by
very low leptin levels and severe obesity [75]. This genetic
condition is too rare to account for the recent obesity
epidemic. It is more likely that most cases of common obesity
in humans are caused by heterozygosity at several genetic loci
for alleles with subtle effects on gene expression and function
rather than bymajor functional disruption of any single gene.
However, humans heterozygous for ob also have lower leptin
levels and increased body fat percentage relative to wild-type
relatives [76].
4.6. Survival. In our experiment, all ApcMin/+ mice had
reduced life-spans, due to anemia or other complications
such as rectal prolapse, caused by the spontaneous intestinal
tumors induced by the mutated Apc gene (Figure 7). Among
these mice which have a limited life-span because of their
tumors, the ob/ob genotype did not affect survival. However,
in the Apc+/+ mice being able to live out their natural life-
span, the ob/obmice had significantly shorter lives compared
with ob/wt and wt/wt mice (Figure 7). The life-span was not
significantly different between the Apc+/+ ob/wt and wt/wt
mice in our experiment, which was also reported by others,
despite increased body weight and decreased leptin levels
[74].
5. Conclusions
We have studied obesity induced both genetically via the ob
mutation and via a 45% fat diet and shown that the high
fat diet severely exacerbates the inherited obesity. In mice
both with genetically-induced obesity and exposed to a 45%
fat diet, spontaneous intestinal tumorigenesis was increased.
The carcinogen- (PhIP-) induced intestinal tumorigenesis
was not further increased by a 45% fat diet. Hyperglucosemia
and insulinemia, indicating disturbed glucose regulation, and
inflammation as seen by increased TNF𝛼 levels, were found
associated with the obesity, implicating these as possible
mechanisms involved in the association between obesity
and intestinal tumorigenesis.The genetically-induced obesity
decreased the life-span of the ob/ob mice.
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